Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 108

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 108
---
 stage programs (1)1,125,342 434,443 690,899 159 %Preclinical stage programs (1)2,767,058 2,678,222 88,836 3 %Other development programs— 22,926 (22,926)(100)%Contra R&D expenses (2)(6,399,167)(4,647,358)(1,751,809)38 %Total direct program costs2,032,655 5,663,405 (3,630,750)(64)%Indirect costs:Personnel-related (including stock compensation)2,701,684 2,965,149 (263,465)(9)%Outside services (including consulting)10,447 4,565 5,882 129 %Facilities-related (including depreciation)36,714 43,633 (6,919)(16)%Other indirect R&D costs152,035 111,979 40,056 36 %Contra R&D expenses(1,207,392)(501,437)(705,955)141 %Total indirect R&D costs1,693,488 2,623,889 (930,401)(35)%Total R&D expenses$3,726,143 $8,287,294 $(4,561,151)(55)%1.The applicable program(s) receive grant funding and/or the Tax Incentive. The amount of R&D expense for the period indicated is shown on a gross basis (i.e., without deducting the amount of contra R&D expense for the applicable program(s). See footnote (2) below. 2.These contra R&D expenses were recognized as follows for the six months ended June 30, 2025 and 2024: (a) Ovaprene, $0.9 million, and $0, respectively; (b) other advanced clinical stage programs, $1.5 million and $0 respectively, (c) Phase 1 and Phase 1-ready clinical stage programs, $0.2 million and $0.5 million, respectively; and (d) preclinical stage programs, $3.8 million and $4.1 million, respectively.

The decrease of approximately $4.6 million in R&D expenses for the six months ended June 30, 2025 as compared to the six months ended June 30, 2024 was primarily attributable to (i)